Clinical trial · Interventional
Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC
Study on Short and Long-term Outcome of Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer
NCT03708783CI-TRIAL-00041778unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to explore the safety and feasibility of laparoscopic spleen-preserving No. 10 lymph node dissection for patients with advanced middle or upper third gastric cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrectomy | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Laparoscopic Surgery | — | UNRESOLVED | — |
| Lymphadenectomy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- No. 10 Lymph Node Dissection group
- description
- Patients with locally advanced upper or middle third gastric cancer will receive laparoscopic total gastrectomy and D2 lymphadenectomy with spleen-preserving No.10 lymph node dissections
- interventionNames
- Procedure: laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection
Primary outcomes (1)
- measure
- the incidence of postoperative complications within 30 days
- timeFrame
- 30 days
Secondary outcomes (1)
- measure
- 3-year disease free survival
- timeFrame
- 36 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients age older than 18 years (including 18 years old); * The primary lesion is located in the upper or middle third of the stomach, including Siewert II type and Siewert III type adenocarcinoma of the esophagogastric junction; * Pathologically confirmed primary gastric adenocarcinoma by endoscopic biopsy (including papillary, tubular, mucinous, signet ring cell and poorly differentiated adenocarcinoma); * Preoperative cancer stage cT2-4aN0-3M0 (according to AJCC-7th TNM staging); * The Eastern Cooperative Oncology Group performance status of 0 or 1; * The American Society of Anesthesiology classes of I, II or III; * Signed Informed consent. Exclusion Criteria: * Pregnant or lactating women; * Suffering from severe mental disorder; * Previous gastrectomy, including endoscopic submucosal dissection and endoscopic mucosal resection; * Integrated or enlarged lymph node with maximum diameter larger than 3 cm according to preoperative imaging, including significantly enlarged or bulky No. 10 lymph nodes; * Siewert I type adenocarcinoma of the esophagogastric junction; * Other malignant diseases (within 5 years); * Other illnesses needed operation concurrently; * Complications (bleeding, perforation or obstruction) required emergency surgery due to primary gastric malignancy; * Pulmonary function tests FEV1 less than 50% of predicted value; * Patient suffered from bleeding tendency disease such as hemophilia or took anti-coagulant medication due to deep vein thrombosis. * Patients with obvious tumor infiltration in the spleen and splenic vessels which require splenectomy.
References
Publications (0)
Data not yet available
No reference posted for this study.